Biological and Pharmaceutical Bulletin · 2011 · 24 citations · 23 references
Life SciencesEndocrinologyPharmacologyCell SignalingSignal TransductionSteroid BiochemistryGonadal HormonesGonadal Steroid HormonesHormone ReceptorsSteroid Hormone BiochemistrySteroid Hormone SignalingSteroid PharmacologyAndrogen Receptor AgonistsAndrogen ReceptorsLuciferase Reporter AssaysLuciferase ReportersPartial Agonist InteractionsPartial Agonist PotencyReporter Gene AssaysSteroid Receptor Agonists
A novel steroid compound, (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11), was found to be a partial agonist of the androgen receptor (AR) in an androgen responsive element (ARE)-luciferase reporter assay. YK11 accelerates nuclear translocation of AR. Furthermore, YK11 does not induce amino/carboxyl-terminal (N/C) interaction and prevents 5-α-dihydrotestosterone (DHT)-mediated N/C interaction. Thus, YK11 activates AR without causing N/C interaction, which may in turn be responsible for the partially agonistic nature of YK11 observed in the ARE-luciferase reporter system. YK11 acts as a gene-selective agonist of AR in MDA-MB 453 cells. The effect of YK11 on gene expression relative to that of androgen agonist varies depending on the gene context. YK11 activated the reporter gene by inducing the translocation of the AR into the nuclear compartment, where its amino-terminal domain (NTD) functions as a constitutive activator of AR target genes. Our results suggest that YK11 might act as selective androgen receptor modulator (SARM).
23
Molecular determinants of resistance to antiandrogen therapy
Charlie D. Chen, Derek S. Welsbie, Chris Tran et al. · Nature Medicine · 2003 · 2.3K citations
Medicine, Endocrinology, Urology +17
Kitty B.J.M. Cleutjens, Conny C. Ehren-van Eekelen, Hetty A. G. M. van der Korput et al. · Journal of Biological Chemistry · 1996 · 415 citations · Full text